# OnCo record lymphoma-ev-fixed-duration-chemotherapy-free-first-line (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "lymphoma-ev-fixed-duration-chemotherapy-free-first-line" ;
  schema:name "Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas"@en ;
  schema:alternateName "Chemotherapy-free first line in follicular and mantle cell lymphoma"@en, "Time-limited bispecific antibody therapy"@en ;
  schema:description "Several treatments now work without chemotherapy, but most are given until the disease comes back. Giving them for a fixed time and stopping is the version patients would choose."@en ;
  schema:url <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  onco:tag "lymphoma-evidence" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/> ;
  onco:terms <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/watchful-waiting/> ;
  onco:trials <https://onco.cc/trials/mosun-lbt-fl/>, <https://onco.cc/trials/mosun-len-mzl/>, <https://onco.cc/trials/enrich/>, <https://onco.cc/trials/relevance/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-patient-voice/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/>, <https://onco.cc/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/>, <https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/> .